Selection of the optimal personalized treatment from multiple treatments with right-censored multivariate outcome measures

被引:1
作者
Siriwardhana, Chathura [1 ]
Kulasekera, K. B. [2 ]
Datta, Somnath [3 ]
机构
[1] Univ Hawaii, John A Burns Sch Med, Dept Quantitat Hlth Sci, Honolulu, HI 96813 USA
[2] Univ Louisville, Dept Bioinformat & Biostat, Louisville, KY USA
[3] Univ Florida, Dept Biostat, Gainesville, FL USA
基金
美国国家卫生研究院;
关键词
Design variables; personalized treatments; single index models; rank aggregation; right-censoring; OPTIMAL TREATMENT REGIMES; TIME;
D O I
10.1080/02664763.2022.2164759
中图分类号
O21 [概率论与数理统计]; C8 [统计学];
学科分类号
020208 ; 070103 ; 0714 ;
摘要
We propose a novel personalized concept for the optimal treatment selection for a situation where the response is a multivariate vector that could contain right-censored variables such as survival time. The proposed method can be applied with any number of treatments and outcome variables, under a broad set of models. Following a working semiparametric Single Index Model that relates covariates and responses, we first define a patient-specific composite score, constructed from individual covariates. We then estimate conditional means of each response, given the patient score, correspond to each treatment, using a nonparametric smooth estimator. Next, a rank aggregation technique is applied to estimate an ordering of treatments based on ranked lists of treatment performance measures given by conditional means. We handle the right-censored data by incorporating the inverse probability of censoring weighting to the corresponding estimators. An empirical study illustrates the performance of the proposed method in finite sample problems. To show the applicability of the proposed procedure for real data, we also present a data analysis using HIV clinical trial data, that contained a right-censored survival event as one of the endpoints.
引用
收藏
页码:891 / 912
页数:22
相关论文
共 38 条
  • [1] Aalen O., 1980, MATH STAT PROBABILIT, P1, DOI [DOI 10.1007/978-1-4615-7397-5_1, 10.1007/978-1-4615-7397-5_1]
  • [2] A LINEAR-REGRESSION MODEL FOR THE ANALYSIS OF LIFE TIMES
    AALEN, OO
    [J]. STATISTICS IN MEDICINE, 1989, 8 (08) : 907 - 925
  • [3] Analysis of randomized comparative clinical trial data for personalized treatment selections
    Cai, Tianxi
    Tian, Lu
    Wong, Peggy H.
    Wei, L. J.
    [J]. BIOSTATISTICS, 2011, 12 (02) : 270 - 282
  • [4] Cui Y., 2021, ARXIV
  • [5] Tree based weighted learning for estimating individualized treatment rules with censored data
    Cui, Yifan
    Zhu, Ruoqing
    Kosorok, Michael
    [J]. ELECTRONIC JOURNAL OF STATISTICS, 2017, 11 (02): : 3927 - 3953
  • [6] Datta S., 2005, Statistical Methodology, V2, P65, DOI DOI 10.1016/J.STAMET.2004.11.003
  • [7] Biomarkers and surrogate endpoints in clinical trials
    Fleming, Thomas R.
    Powers, John H.
    [J]. STATISTICS IN MEDICINE, 2012, 31 (25) : 2973 - 2984
  • [8] On optimal treatment regimes selection for mean survival time
    Geng, Yuan
    Zhang, Hao Helen
    Lu, Wenbin
    [J]. STATISTICS IN MEDICINE, 2015, 34 (07) : 1169 - 1184
  • [9] Genz A, 2017, MVTNORM MULTIVARIATE
  • [10] A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
    Hammer, SM
    Katzenstein, DA
    Hughes, MD
    Gundacker, H
    Schooley, RT
    Haubrich, RH
    Henry, WK
    Lederman, MM
    Phair, JP
    Niu, M
    Hirsch, MS
    Merigan, TC
    Blaschke, TF
    Simpson, D
    McLaren, C
    Rooney, J
    Salgo, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (15) : 1081 - 1090